Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight

Summary

DelveInsight reports that the non-metastatic prostate cancer market is expected to grow at a 4% CAGR through 2036, driven by increased disease awareness and diagnostic advances. Myovant's Relugolix (ORGOVYX) is highlighted among advanced therapies in development for this indication.